Dysregulated Tyrosine Kinase Signaling in Leukemia

This study has been completed.
Sponsor:
Information provided by:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT00277056
First received: January 11, 2006
Last updated: January 6, 2010
Last verified: April 2008
  Purpose

Dysregulated Tyrosine Kinase Signaling in Leukemia


Condition
Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dysregulated Tyrosine Kinase Signaling in Leukemia

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Biospecimen Retention:   Samples With DNA

blood bone marrow


Enrollment: 30
Study Start Date: May 2002
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Detailed Description:

Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

people with leukemia

Criteria

Inclusion Criteria:

  • Patients must have newly diagnosed or relapsed leukemia.
  • Patients must sign an informed consent.
  • Patients will not be excluded if they are receiving chemotherapy.
  • Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.
  • Patients must be => 18 years of age.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00277056

Locations
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Ian Rabinowitz, MD University of New Mexico
  More Information

No publications provided

Responsible Party: Ian Rabinowitz, MD, University of New Mexico CRTC
ClinicalTrials.gov Identifier: NCT00277056     History of Changes
Other Study ID Numbers: 1602C
Study First Received: January 11, 2006
Last Updated: January 6, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of New Mexico:
leukemia

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on July 24, 2014